Cargando…

Estimating cost savings of pharmacogenetic testing for depression in real-world clinical settings

The burden of depression significantly impacts the patient, the health care system, and society, at large. Medication management guided by pharmacogenetics has been shown to increase therapeutic efficacy and improve symptoms in patients diagnosed with depression, but limited data are available on th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maciel, Alejandra, Cullors, Ali, Lukowiak, Andrew A, Garces, Jorge
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5764291/ https://www.ncbi.nlm.nih.gov/pubmed/29386895 http://dx.doi.org/10.2147/NDT.S145046

Ejemplares similares

Cost-Effectiveness of a Pharmacogenetic Test to Guide Treatment for Major Depressive Disorder
por: Groessl, Erik J., et al.
Publicado: (2018)

Initial assessment of the benefits of implementing pharmacogenetics into the medical management of patients in a long-term care facility
por: Saldivar, Juan-Sebastian, et al.
Publicado: (2016)

Contribution of Pharmacogenetic Testing to Modeled Medication Change Recommendations in a Long-Term Care Population with Polypharmacy
por: Sugarman, Elaine A., et al.
Publicado: (2016)

Pharmacogenetics in Practice: Estimating the Clinical Actionability of Pharmacogenetic Testing in Perioperative and Ambulatory Settings
por: Smith, D. Max, et al.
Publicado: (2020)

The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real‐World Setting
por: Cavallari, LH, et al.
Publicado: (2017)

Economic Evaluation of Implementing a Novel Pharmacogenomic Test (IDgenetix(®)) to Guide Treatment of Patients with Depression and/or Anxiety
por: Najafzadeh, Mehdi, et al.
Publicado: (2017)

Delivering pharmacogenetic testing in a primary care setting
por: Mills, Rachel, et al.
Publicado: (2013)

Transitioning ifosfamide chemotherapy regimens to the ambulatory setting: reviewing cost savings and safety profile
por: Banh, Cindy, et al.
Publicado: (2021)

Cost Effectiveness of Pharmacogenetic Testing for Drugs with Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines: A Systematic Review
por: Morris, Sarah A., et al.
Publicado: (2022)

Real-World Efficiency of Pharmacogenetic Screening for Carbamazepine-Induced Severe Cutaneous Adverse Reactions
por: Chen, Zhibin, et al.
Publicado: (2014)

Estimated Cost Savings: Everyone With Diabetes Counts (EDC) Program
por: Silveira, Lori J., et al.
Publicado: (2018)

A Cost-Saving Hemodialysis Scheme in Limited-Resource Settings
por: Aoun, Mabel
Publicado: (2022)

Positively Correlated Samples Save Pooled Testing Costs
Publicado: (2021)

Estimated cost of asthma in outpatient treatment: a real-world study
por: Costa, Eduardo, et al.
Publicado: (2018)

What Are the Barriers and Enablers to the Implementation of Pharmacogenetic Testing in Mental Health Care Settings?
por: Jameson, Adam, et al.
Publicado: (2021)

Pharmacogenetics and Depression: A Critical Perspective
por: Corponi, Filippo, et al.
Publicado: (2019)

Real-World Clinical Effectiveness and Cost Savings of Liraglutide Versus Sitagliptin in Treating Type 2 Diabetes for 1 and 2 Years
por: Li, Qian, et al.
Publicado: (2018)

Pharmacogenetic testing among patients with depression in a US managed care population
por: Anderson, Heather D., et al.
Publicado: (2022)

Clinical Phenotypes Characterization in Pharmacogenetics Testing Trials for Major Depressive Disorder Treatment
por: Minelli, A.
Publicado: (2022)

Minimally important difference in cost savings: Is it possible to identify an MID for cost savings?
por: Dooley, Mary, et al.
Publicado: (2021)

Software life cycle management standards: real-world solutions and scenarios for savings
por: Wright, David
Publicado: (2011)

Investigating Real‐World Clopidogrel Pharmacogenetics in Stroke Using a Bioresource Linked to Electronic Medical Records
por: Tornio, Aleksi, et al.
Publicado: (2017)

Real-World Cost Savings Demonstrated by Switching Patients with Refractory Diabetic Macular Edema to Intravitreal Fluocinolone Acetonide (Iluvien): A Retrospective Cost Analysis Study
por: Ch’ng, Soon W., et al.
Publicado: (2017)

Real-World Impact of Switching From Insulin Glargine (Lantus(®)) to Basaglar(®) and Potential Cost Saving in a Large Public Healthcare System in Saudi Arabia
por: AlRuthia, Yazed, et al.
Publicado: (2022)

Pharmacist-Initiated Pre-Emptive Pharmacogenetic Panel Testing with Clinical Decision Support in Primary Care: Record of PGx Results and Real-World Impact
por: van der Wouden, Cathelijne H., et al.
Publicado: (2019)

Delivery of Pharmacogenetic Testing with or without Medication Therapy Management in a Community Pharmacy Setting
por: Haga, Susanne B, et al.
Publicado: (2021)

Estimating Savings Opportunities From Therapeutic Substitutions of High-Cost Generic Medications
por: Socal, Mariana P., et al.
Publicado: (2022)

Estimated Indirect Cost Savings of Using Telehealth Among Nonelderly Patients With Cancer
por: Patel, Krupal B., et al.
Publicado: (2023)

Arduino projects to save the world
por: Premeaux, Emery, et al.
Publicado: (2011)

Can Finance Save the World?
por: Badré, Bertrand
Publicado: (2018)

Saving the World's Terrestrial Megafauna
por: Ripple, William J., et al.
Publicado: (2016)

Primary care and mental health providers’ perceptions of implementation of pharmacogenetics testing for depression prescribing
por: Vest, Bonnie M., et al.
Publicado: (2020)

The Potential Utility of Pharmacogenetic Testing in Psychiatry
por: Gardner, Kathryn R., et al.
Publicado: (2014)

Variant Interpretation in Current Pharmacogenetic Testing
por: Luvsantseren, Sally, et al.
Publicado: (2020)

The Utility of Pharmacogenetics Testing in Psychiatric Populations
por: Jürgens, Gesche
Publicado: (2021)

EXPERIENCE OF PHARMACOGENETIC TESTING IN THE TREATMENT OF ANTIPSYCHOTICS
por: Kaydan, M., et al.
Publicado: (2023)

Prevention is life- and cost-saving
por: Baussano, Iacopo, et al.
Publicado: (2020)

Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet?
por: Verbelen, M, et al.
Publicado: (2017)

Oxycodone/naloxone versus tapentadol in real-world chronic non-cancer pain management: an observational and pharmacogenetic study
por: Barrachina, Jordi, et al.
Publicado: (2022)

Cost-effectiveness of HIV Prevention Interventions: Estimates from Real-world Implementation Needed
por: Peebles, Kathryn, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ns27likks24tpmk24gd7dgo296